Summary: In order to understand the insulinomimetic activity of zinc(II) complexes, we studied the metallokinetic features of zinc in the blood of normal rats given the zinc complexes, bis(maltolato)zinc(II) (Zn(mal) 2 ) and bis(6-methylpicolinato)zinc(II) (Zn(6mpa) 2 ) by comparing each of them with an ionic form of zinc chloride (ZnCl 2 ). The bioavailability of the zinc(II) complexes following oral administration was enhanced to 1.4-1.5-fold that of ZnCl 2 with respect to zinc level. Based on the results of a metallokinetic analysis and administration method in normal rats, we examined the antidiabetic ability of the zinc(II) complexes in GK rats, a model animal of type 2 diabetes mellitus. High blood glucose levels of GK rats were normalized following intraperitoneal injections and oral administration of the zinc(II) complexes, in which the Zn(6mpa) 2 complex was found to be more eŠective than Zn(mal) 2 . The present results are noteworthy, not only due to their potential relevance for clinical application, but also for the development of new zinc(II) complexes.
Introduction
A new concept for treating diabetes mellitus has been developed that involves the use of metal complexes such as vanadium, 1) manganese, 2) cobalt, 3) and selenium, 4) in place of insulin injection and synthetic therapeutics for type 1 (insulin-dependent diabetes mellitus; IDDM) and type 2 (non-insulin-dependent diabetes mellitus; NIDDM) diabetes mellitus. Recently, we proposed another candidate, a group of zinc(II) complexes, including bis(maltolato)zinc(II) (Zn(mal) 2 ), 5) bis(amino acid)zinc(II) (Zn(aa)2), 6) and bis(picolinato)zinc(II) (Zn(pic)2), 7) as well as an analogue of the latter, the bis(6-methylpicolinato)Zn(II) (Zn(6mpa)2) complex. These candidates were chosen on the basis of the results of their in vitro insulinomimetic activities in isolated rat adipocytes and in vivo hypoglycemic potential in type 2 diabetic model KK-A y mice that had been administered the complexes daily via intraperitoneal injections. To develop clinically useful insulinomimetic zinc(II) complexes, demonstration of the eŠectiveness of oral administration will be necessary, as well clariˆcation of the pharmacokinetic features of the complexes.
Recently, it was reported that vanadyl sulfate (VOSO4; VS) was shown to be eŠective in treating subjects with type 2 diabetes mellitus when they were given an oral daily dose of 150 mg for 6 weeks. 8) In that study, plasma vanadium concentrations were below 10 mg W L before treatment, whereas after treatment, an increase to 104±18 mg W L after 6 weeks of VS administration was observed. This result indicated that control of the plasma glucose concentration can be achieved by VS treatment and that the monitoring of vanadium concentrations in the blood of the subjects is necessary with such treatment. We then analyzed the pharmacokinetic feature of VS and found that the bioavailability of VS is very low (4.8z) on oral administration but can be enhanced to approximately 10-13z via jejunum and ileum administration. 9) Based on these results, we proposed the administration to diabetic patients of a capsule containing VS that had been coated such that it would ensure vanadium absorption at the jenunum and ileum.
10) Furthermore, we indicated the usefulness of pharmacokinetic study for the development of therapeutic agents.
Using zinc(II) complexes, we examined the pharmacokinetic features of zinc in the blood of normal rats given zinc(II) ion and zinc(II) complexes. On the basis of the obtained pharmacokinetic parameters, we tested the in vivo hypoglycemic activity of the zinc(II) complexes following oral administration in GK rats, a reliable animal model of type 2 diabetes with low insulin secretion, non-obesity, and modest hyperglycemia. [11] [12] [13] On the basis of the results of pharmacokinetic study, the present results demonstrated for theˆrst time that the zinc(II) complexes Zn(mal)2 and Zn(6mpa)2 are eŠective for the treatment of diabetes in a rat model when orally administered.
Materials and Methods
Materials: Zinc chloride (ZnCl 2 ), nitric acid (HNO 3 for the detection of poisonous metals), perchloric acid (HClO4 for the detection of poisonous metals) and hydrogen peroxide (H2O2 for the atomic absorption in the spectrochemical analysis) for wet digestion, and standard solutions of Zn for the atomic absorption spectrometry (AAS) measurements were all purchased from Wako Pure Chemicals (Osaka, Japan). Pentobarbital (50 mg W mL), sodium heparin, and Aron Alpha (an instant adhesive for surgery) were purchased from Dainabot Co. (Osaka, Japan), Shimizu Co. (Osaka, Japan), and Sankyo Co. (Tokyo, Japan), respectively. g-Cyclodextrin was obtained from Tokyo Kasei Organic Chemicals (Tokyo, Japan). All other compounds used were of analytical reagent grade. Bis(maltolato)zinc(II) (Zn(mal) 2 ) and bis(6-methylpicolinato)zinc(II) (Zn (6mpa)2) were synthesized by previously reported methods.
5-7)
Animals: Normal male Wistar rats (8 weeks old, 240-250 g) and GK rats (4 weeks old, 70-80 g) were purchased from Shimizu Experimental Material Co. (Kyoto, Japan) and CLEA Japan Inc. (Tokyo, Japan), respectively. Before both single and chronic administration, rats were housed in a temperature-controlled room at 23±19 C on a 12 h lightW 12 h dark cycle. Rats were fed a standard laboratory diet (MF Oriental Yeast Co., Tokyo) and were given tap water ad libitum. Normal rats were fasted overnight for 12 h before single administration. ZnCl2 was dissolved in a physiological saline (0.9z NaCl) for the administration. Zn(mal)2 and Zn(6mpa) 2 were suspended in 13z g-cyclodextrin solution for the injection and the oral administration. All animal experiments were approved by the Experimental Animal Research Committee of Kyoto Pharmaceutical University and were performed according to the Guidelines for Animal Experimentation of Kyoto Pharmaceutical University.
Metallokinetic analyses in normal rats given ZnCl2, Zn(mal)2, and Zn(6mpa)2:
Intravenous administration Each zinc compound was intravenously injected through the right jugular vein of normal rats (n＝3) at a dose of 1 mg (15 mmol) zinc W kg body weight under anesthesia with pentobarbital (30 mg W kg body weight). Blood samples (60 mL) were periodically collected from the jugular vein by puncture with a heparinized syringe using a 26-G needle under light ether anesthesia.
Oral administration Each solution of three zinc compounds was intragastrically administered to the normal rats (n＝3-5) at a dose of 10 mg (154 mmol) zinc W kg body weight, in which zinc concentration was 77 mmol W L and administration volume was 2 mL W kg body weight, using a stainless sonde. Blood samples were collected by the same method as that used for the intravenous administration.
Intraduodnal administration Normal rats (n＝3-5) were anaesthetized by intraperitoneal injection of pentobarbital at a dose of 30 mg W kg body weight. Rats were then placed on a Deltaphase Isothermal Pad kept at 379 C (model 39 DP, Braintree Scientiˆc Inc., Braintree, USA). For intraduodenal administration of the three zinc compounds to normal rats, an incision (2 cm) was made in the epigastrium and each solution was administered into the duodenum through the stomach at a dose of 10 mg (154 mmol) zinc W kg body weight under anesthesia using a syringe with a 26-G needle. The top of each needle was positioned at 3 cm distal to the point where the duodenum curves towards the midline. After administration, the puncture made in the stomach wall was closed with a drop of tissue cement (Aron Alpha) and the abdominal incision was sutured. The normal rats awoke at approximately 1 h after administration. Blood samples were collected by the same method as that used for the intravenous administration.
Measurement of zinc concentrations in the blood Zinc concentrations in the blood were measured using a graphite furnace atomic absorption spectrometer (AAS) (AA6500 and GFA-6000, Shimadzu Co., Tokyo, Japan). Brie‰y, 60 mL of blood were heated at 2009 C with 60z HNO 3 , 30z H 2 O 2 , and 60z HClO 4 in 50 mL beakers. The procedure was repeated, if necessary. When the residue became white, the dried samples were dissolved in 1 mL of 6z HNO3. Then, the zinc concentrations were measured by AAS. Zinc concentrations were calculated using a calibration curve at a concentration range of 0-10 ng W mL (0-154 nM). The detection limit was 0.5 ng W mL (8 nM). The correlation coe‹cient of linear regression was rÀ0.9999 for a total of 5 zinc concentrations. The measurement conditions for the AAS were as follows: drying, 909 C for 10 sec; ashing, 3009 C for 30 sec; and atomizing, 15009 C for 4 sec.
Pharmacokinetic analyses of the blood The time course of zinc concentrations in the blood, in which zinc concentrations in the blood at each sampling time after the administration of saline (0.9z NaCl) alone were subtracted from those at each sampling time after the administration of the zinc complexes dissolved in physiological saline (0.9z NaCl), was evaluated on the basis of non-compartment pharmacokinetic analysis (moment analysis).
14) The area under the zinc concentration in the blood-time curve (AUC), maximal zinc concentration (Cmax), mean residence time (MRT) of zinc, and time required to attain Cmax (Tmax) were estimated model-independently. Bioavailability (Fa) in each group was calculated by the following equation:
Chronic administration of Zn(mal)2 and Zn(6mpa)2 to GK rats: GK rats were allowed free access to standard solid food and tap water for one month (4 weeks) from the purchase before chronic administration of zinc complexes. The body weight of GK rats and the intake of solid food and drinking water in each rat were measured daily during the experiments. GK rats (n＝8) were given Zn(mal)2 intraperitoneally at a dose of 62 mmol (4 mg) zinc W kg body weight for 30 days. Another group of GK rats (n＝10) was administered Zn(6mpa)2 intraperitoneally at a dose of 62 mmol (4 mg) zinc W kg body weight for theˆrst 16 days, at a dose of 8 mmol (0.5 mg) for 6 days, and then at a dose of 31 mmol (2 mg) for another 23 days. These zinc complexes were also administered to GK rats by oral administration. Zn(mal)2 was given orally to GK rats (n＝6) at doses of 462 mmol (30 mg) zinc W kg body weight for 15 days and then 308 mmol (20 mg) for another 15 days. Zn(6mpa)2 was given orally at doses of 462 mmol (30 mg) zinc W kg body weight for theˆrst 16 days, then 77 mmol (5 mg) for 6 days, and 231 mmol (15 mg) for another 23 days (n＝ 10). During the administration period, blood glucose levels were measured daily using Fuji Dri-Chem Slide and Fuji Dri-Chem 1000 (Fuji Film Med. Co., Tokyo, Japan).
Oral glucose tolerance tests: Before and after the administration of the zinc complexes to GK rats, 40z glucose solution (2 g W kg body weight) was intragastrically administered to the rats in the fasting state (12 h). Blood samples were obtained from the tail vein at 0, 15, 30, 60, 90, 120, 180, and 240 min after administration. Blood glucose levels were determined using Fuji DriChem Slide and Fuji Dri-Chem 1000 (Fuji Film Med. Co., Tokyo, Japan).
Measurement of serum parameters and HbA1c: Serum parameters and HbA1c were determined before and after the administration of zinc complexes. Serum glucose levels (GLU), blood urea nitrogen (BUN), glutamic pyruvic transaminase (GPT), glutamic oxaloacetic transaminase (GOT), total cholesterol (TCHO), and triglyceride (TG) were determined with Fuji Dri-Chem 3000 (Fuji Film Med. Co., Tokyo, Japan). Serum insulin was measured by GLAZYME insulin-EIA test (Wako Pure Chemicals). HbA1c was measured by a DCA 2000 system (Bayer Co., Tokyo, Japan).
Statistical analyses: All experiments results were expressed as the arithmetic mean and standard deviation (s.d.) of measurements. Statistical analysis was performed using analysis of variance at a 5z (Pº0.05) or 1z (Pº0.01) signiˆcance level.
Results
Metallokinetic analysis: ZnCl2, Zn(mal)2 or Zn (6mpa)2 was given to normal rats by intravenous (i.v.) injection (15 mmol W kg body weight), oral administration (154 mmol W kg body weight), and intraduodenal (i.d.) administration (154 mmol W kg body weight), and the zinc concentration in the blood was measured. The time course of zinc concentrations in the blood of rats and the calculated metallokinetic parameters are summarized in Fig. 1-3 and Table 1 , respectively. Although the mean endogenous zinc concentration in the blood of rats was 100 nmol W mL, the zinc concentration in the blood of rats given the vehicle (0.9z NaCl) alone changed at each sampling time. Therefore, in calculation of metallokinetic parameters, the zinc concentration in the blood due to the administration of zinc complexes was obtained from the zinc concentration after administration of zinc compounds by subtracting the concentration in the blood of rats given the vehicle alone at each sampling time. No signiˆcant diŠerences in the metallokinetic parameters in rats given the zinc compounds by i.v. administration were observed. CLtot values obtained for the data by i.v. administration were used for calculating the Fa value on the assumption of a linear condition, which is deˆned as bioavailability from the non-intravenous administration sites.
To evaluate the intestinal absorption of the zinc compounds, the three zinc compounds were given to rats by oral and i.d. administration. The Fa values of rats received oral Zn(mal)2 and Zn(6mpa)2 (37.3z and 32.6z, respectively) were higher than that of rats given ZnCl2 (23.6z). The Cmax values for the three compounds given by oral administration were almost unchanged.
Administration of zinc complexes to GK rats: Because the bioavailability in terms of zinc concentration in the blood was found to enhance on oral administration of the zinc(II) complexes in normal rats by metallokinetic analysis, Zn(mal)2 or Zn(6mpa)2 were given to GK rats by daily oral administration for 30 or 45 days, in which the data were compared with those for intraperitoneal (i.p.) injection. Blood glucose levels signiˆcantly decreased by oral administration and i.p. injection of the zinc complexes (Fig. 4) . Then we evaluated whether or not the diabetes in GK rats were improved by the glucose tolerance test using oral 2 g glucose W kg body weight (Fig. 5) . The fasting blood glucose levels in the GK rats given zinc complexes were not signiˆcantly diŠerent from those in the untreated GK rats. However, the maximum level of blood glucose in GK rats treated orally with Zn(6mpa)2 was signiˆcantly lower than that in the untreated GK rats. The serum parameters in GK rats treated with the zinc complexes by i.p. injection and oral administration are summarized in Table 2 . The serum glucose levels decreased upon i.p. administration of the two zinc complexes and on oral administration of Zn(6mpa)2. HbA1c level of GK rats was lower than that of the untreated GK rats when Zn(mal)2 was administered by intraperitoneal injection. Insulin levels were improved in the GK rats given the zinc complexes compared with those of the untreated rats. BUN levels decreased after i.p. administration of the two zinc complexes and after oral administration of Zn(6mpa) 2 . GPT levels were unchanged by administration of the zinc complexes. GOT levels decreased by i.p. administration of Zn(mal)2 and on oral administration of the two zinc complexes. TCHO levels decreased by i.p. injection and by oral administration of Zn(6mpa)2. TG levels decreased after i.p. administration of the two zinc complexes, as well as following oral administration of Zn(6mpa)2.
Discussion
Diabetes mellitus (DM) is a metabolic disease which causes hyperglycemia and many other complications. 15) Recently, it was reported that a variety of metal ions have insulinomimetic activity. [16] [17] [18] Coulston and Dandona found that zinc, which is one of the essential elements in animals and humans, stimulates lipogenesis in rat adipocytes, which is similar to the action of insulin. 19) Furthermore, previous studies have demonstrated that zinc acts on adipocytes and promotes the induction of leptin; it also acts on the pancreas, and therefore helps insulin to bind with the insulin receptor, resulting in improvement of the conditions of type 2 DM. 20) Generally, it is known that the complexation of free metal ions lowers the toxicity of metal ions and promotes their absorption into the blood. 21, 22) We indicated that vanadyl (IV) complexes with picolinate and 6-methyl-picolinate exhibit high insulinomimetic activity 23, 24) and that they increase the bioavailability of vanadyl species. 9) Therefore, weˆrst investigated the absorption processes of two zinc(II) complexes, bis(maltolato)zinc(II) (Zn(mal)2) and bis(6-methylpicolinato)zinc(II) (Zn(6mpa)2), by comparing them with that of an ionic form of zinc chloride (ZnCl2). From the results, the Fa values of two zinc(II) complexes after oral administration were found to be 1.4-1.5-fold higher than that of ZnCl2 (Table 1) , similarly to enhancement of the absorption of the vanadyl complexes. 9, 10) The bioavailability of BioZn-AAS, a zinc gluconate stabilized with glycine, was reported as being 25-28z. 25) In the present study, ZnCl2 was found to be absorbed to the same extent (23.6z) ( Table 1) . However, the zinc complexes were found to be enhanced after their oral administration.
On the basis of the metallokinetic analysis of zinc compounds in normal rats, we examined whether or not the zinc complexes exhibit hypoglycemic activity on oral administration in GK rat, type 2 DM model animal. Previously, Zn(mal)2 and Zn(6mpa)2 given by i.p. injection were both found to show hypoglycemic activity in KK-A y mice, a type 2 DM model. 5, 7) The GK rat is one of the most reliable models for type 2 diabetes because of the many primary features manifested, including fasting hyperglycemia, impaired insulin response to glucose, hepatic and peripheral insulin resistance, and typical complications.
11)
The treatment with Zn(mal)2 and Zn(6mpa)2 lowered the blood glucose levels in GK rats (Fig. 4) . HbA1c level, which indicates average blood glucose levels over a long period, is known to increase with aging of diabetic states. In the present study, however, HbA 1c levels were unchanged by Zn(II) complexes. Insulin levels of GK rats were signiˆcantly decreased by treatment of Zn(II) complexes. Type 2 DM is resulted from a relative lack of insulin secretion or the decline of insulin sensitivity in targeting organs. From the decrease of insulin levels of GK rats in the present study, insulin sensitivity was thought to enhance by treatment of zinc(II) complexes, suggesting zinc(II) complexes improve the insulin resistance of type 2 DM. BUN, GPT, GOT, TCHO and TG levels were unchanged or decreased in zinc(II) complexes treated GK rats, suggesting that zinc(II) complexes appear to be non-toxic to the renal and hepatic functions, and to improve the hyperlipidemia in diabetes mellitus.
Conclusion
On the basis of the results of the metallokinetic study in normal rats receiving two zinc(II) complexes, the present study revealed for theˆrst time that oral administration of either of Zn(mal) 2 and Zn(6mpa) 2 , lowered the blood glucose levels in GK rats with type 2 DM. These results will be useful not only for clinical application in the future but also for developing new and more eŠective zinc(II) complexes.
